Global Locations

Bicalutamide D5



Chemical Properties of 'Bicalutamide D5'

CAT No. :

CS-O-02645
CAS Registry No. : 90357-06-5 (Unlabeled)
Category : Isotope Labelled Compounds
Molecular Weight: 435.40
Molecular Formula : C₁₈H₉D₅F₄N₂O₄S



OTHER INFORMATION of 'Bicalutamide D5'
Purity : Not less than 95%
Therapeutic : Anti-Cancer / Oncology
Isotopic Enrichment : Not less than 98%
Purity : Not less than 95%
Therapeutic : Anti-Cancer / Oncology
Isotopic Enrichment : Not less than 98%
IUPAC Name :N-[4-cyano-3-(trifluoromethyl)phenyl]-3-(4-fluorophenyl)sulfonyl-2-hydroxy-2-methylpropanamide
Applicationnotes :"Labeled Bicalutamide, intended for use as an internal standard for the quantification of Bicalutamide by GC- or LC-mass spectrometry."
Synonym :Not available
References :"Tucker; H,; et al,: J, Med, Chem,; 31; 954 (1988); Cockshott; I,D,; et al,: Eur, Urol,; 18; Suppl, 3; 10 (1990); Cockshott; I,; et al,: Br, J, Clin, Pharm,; 36; 339 (1993);"
Smileys :FC(F)(C(C=C(NC(C(C([2H])([2H])[2H])(O)C([2H])([2H])[S](=O)(C1=CC=C(F)C=C1)=O)=O)C=C2)=C2C#N)F
Appearance :NA
Color / Form :Crystals from 1:1 (v/v) mix of ethyl acetate and petroleum ether
Melting Point :191-193 °C
Use Classification :Human Drugs -> FDA Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book) -> Active Ingredients
Hazard Class :Skin Irrit. 2 (92.86%)
MeSH Entry Terms :4'-cyano-3-(4-fluorophenylsulfonyl)-2-hydroxy-2-methyl-3'-(trifluoromethyl)propionanilide
Other Synonyms :bicalutamide
Removed Synonyms :Bicalutamid
Vapor Pressure : 7.54X10-15 mm Hg at 25 °C (est)
Other Experimental Properties :Hydroxyl radical reaction rate constant = 2.99X10-11 cu cm/molec-sec at 25 °C (est)
Label Ingredient : BICALUTAMIDE
NDC Code :0904-6019-46, 16714-816-01, 16714-816-02, 16729-023-01, 16729-023-10, 47335-485-08, 47335-485-18, 47335-485-83, 47335-485-88, 54868-4503-0 ... total 41.
Disposal Methods :SRP: At the time of review, criteria for land treatment or burial (sanitary landfill) disposal practices are subject to significant revision. Prior to implementing land disposal of waste residue (including waste sludge), consult with environmental regulatory agencies for guidance on acceptable disposal practices.
Hepatotoxicity :Bicalutamide therapy is associated with mild, asymptomatic and transient elevations in serum aminotransferase levels in approximately 6% of patients. The frequency and height of the ALT elevations appears to be less with bicalutamide than flutamide. Similarly, there have been rare case reports of clinically apparent liver injury due to bicalutamide, but less frequently than with flutamide. In the Spanish pharmacovigilance study, there were 11 reports of hepatotoxicity from bicalutamide, none of which were fatal. On the other hand, the product label for bicalutamide mentions that a few cases of fatal hepatic failure have been reported. The clinical pattern of liver injury with bicalutamide appears to resemble that of flutamide. The latency to onset is usually 2 to 3 months, but can be shorter with reexposure and occasionally arises 4 to 6 months after starting. The typical pattern of serum enzyme elevations is hepatocellular and severe, fulminant cases have been described. Rash, fever and eosinophilia are not common and autoantibody formation is not described.
Drug Induced Liver Injury :bicalutamide
Interactions :In vitro protein-binding studies have shown that bicalutamide can displace coumarin anticoagulants from binding sites. Prothrombin times should be closely monitored in patients already receiving coumarin anticoagulants who are started on /bicalutamide/.
Antidoteand Emergency Treatment :Maintain an open airway and assist ventilation if necessary. Treat coma, seizures, hypotension, and arrhythmias if they occur. Treat nausea and vomiting with metoclopramide and fluid loss caused by gastroenteritis with intravenous crystalloid fluids. Bone marrow depression should be treated with the assistance of an experienced hematologist or oncologist. Extravasation: Immediately stop the infusion and withdraw as much fluid as possible by negative pressure on the syringe. ... /For/ decontamination administer activated charcoal orally if conditions are appropriate. Gastric lavage is not necessary after small to moderate ingestions if activated charcoal can be given promptly. Because of the rapid intracellular incorporation of these agents, dialysis and other extracorporeal removal procedures are generally not effective.
Human Toxicity Excerpts :/HUMAN EXPOSURE STUDIES/ ... Sixteen patients with prostatic cancer (stage C to D) were given 10, 30, 50, 80 or 100 mg of bicalutamide orally daily for 12 weeks. Adverse reactions were observed in 8 out of 16 patients, but almost all were mild. Breast pain, gynecomastia and hot flushes were observed in 6 patients. Adverse reactions regarding liver function tests were observed in 3 patients. These were increased glutamic-oxalacetic transaminase (GOT), glutamic-pyruvic transaminase (GPT), alkaliphosphatase (AL-P) or gamma guanosine 5'-triphosphate (gamma-GTP). However, during or after the treatment period the elevated values were reversed to the pretreatment level. ...
Non Human Toxicity Excerpts :/LABORATORY ANIMALS: Chronic Exposure or Carcinogenicity/ A small increase in the incidence of hepatocellular carcinoma in male mice given 75 mg/kg/day of bicalutamide and an increased incidence of benign thyroid follicular cell adenomas in rats given 5 mg/kg/day and above were recorded. These neoplastic changes were progressions of non-neoplastic changes related to hepatic enzyme induction observed in animal toxicity studies. Enzyme induction has not been observed following bicalutamide administration in man.
Protein Binding :96%
Exact Mass :430.06104075
InChI :InChI=1S/C18H14F4N2O4S/c1-17(26,10-29(27,28)14-6-3-12(19)4-7-14)16(25)24-13-5-2-11(9-23)15(8-13)18(20,21)22/h2-8,26H,10H2,1H3,(H,24,25)
InchIKey :LKJPYSCBVHEWIU-UHFFFAOYSA-N
Canonical SMILES :CC(CS(=O)(=O)C1=CC=C(C=C1)F)(C(=O)NC2=CC(=C(C=C2)C#N)C(F)(F)F)O
Isomeric SMILES :CC(CS(=O)(=O)C1=CC=C(C=C1)F)(C(=O)NC2=CC(=C(C=C2)C#N)C(F)(F)F)O
Product Description :N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropanamide is a member of the class of (trifluoromethyl)benzenes that is 4-amino-2-(trifluoromethyl)benzonitrile in which one of the amino hydrogens is substituted by a 3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropanoyl group. It is a member of (trifluoromethyl)benzenes, a monocarboxylic acid amide, a member of monofluorobenzenes, a nitrile, a sulfone and a tertiary alcohol.
Custom Duty : Applicable
Port of Loading : Canada
Expected Dispatch : 15-Aug-2022
Taxes : Not Applicable
Refund Policy : 30-days money back
Custom Duty : Applicable
Port of Loading : Canada
Expected Dispatch : 15-Aug-2022
Taxes : Not Applicable
Refund Policy : 30-days money back


More information about Bicalutamide


Bicalutamide, sold under the brand name Casodex among others, is an antiandrogen medication that is primarily used to treat prostate cancer. It is typically used together with a gonadotropin-releasing hormone (GnRH) analogue or surgical removal of the testicles to treat advanced prostate cancer. To a lesser extent, it is used for early prostate cancer at a higher dosage as a monotherapy without castration. Bicalutamide is also used to treat excessive hair growth and scalp hair loss in women, as a component of feminizing hormone therapy for transgender women, to treat early puberty in boys, and to prevent overly long-lasting erections in men. It is taken by mouth.

Common side effects in men include breast enlargement, breast tenderness, and hot flashes. Other side effects in men include feminization and sexual dysfunction. Some side effects like breast changes and feminization are minimal when combined with castration. While the medication appears to produce few side effects in women, its use in cisgender women is not recommended by the Food and Drug Administration (FDA) at this time. Use during pregnancy may harm the baby. Bicalutamide causes elevated liver enzymes in around 1% of people. Rarely, it has been associated with cases of liver damage, lung toxicity, and sensitivity to light. Although the risk of adverse liver changes is small, monitoring of liver function is recommended during treatment.

Bicalutamide is a member of the nonsteroidal antiandrogen (NSAA) group of medications. It works by selectively blocking the androgen receptor (AR), the biological target of the androgen sex hormones testosterone and dihydrotestosterone (DHT). It does not lower androgen levels. The medication can have some estrogen-like effects in men when used as a monotherapy due to increased estradiol levels. Bicalutamide is well-absorbed, and its absorption is not affected by food. The elimination half-life of the medication is around one week. It shows peripheral selectivity in animals, but crosses the blood\u2013brain barrier and affects both the body and brain in humans.

Bicalutamide was patented in 1982 and approved for medical use in 1995. It is on the World Health Organization's List of Essential Medicines. Bicalutamide is available as a generic medication. The drug is sold in more than 80\u00a0countries, including most developed countries. It is the most widely used antiandrogen in the treatment of prostate cancer, and has been prescribed to millions of men with the disease.





This page contains information about Bicalutamide D5 , Bicalutamide D5 cas, Bicalutamide D5 synthesis, Bicalutamide D5 suppliers

What is Bicalutamide D5 ?
Bicalutamide D5 falls under Isotope Labelled Compounds of Bicalutamide."Labeled Bicalutamide, intended for use as an internal standard for the quantification of Bicalutamide by GC- or LC-mass spectrometry."
What is the CAS Number of Bicalutamide D5?
The CAS Number of Bicalutamide D5 is 90357-06-5 (Unlabeled)
Who are the suppliers of Bicalutamide D5?
CLEARSYNTH is a worldwide supplier of Bicalutamide D5

Looking for a discounted price or need more info for 'Bicalutamide D5 (CS-O-02645)' ?

If you are looking for Bulk purchase, Discounted Price, etc. please share your email and the exact quantity you are looking for, our team will respond to you within 30 mins with all the required information.

Looking for a discounted price or need more info for 'Bicalutamide D5 (CS-O-02645)' ?

If you are looking for Bulk purchase, Discounted Price, etc. please share your email and the exact quantity you are looking for, our team will respond to you within 30 mins with all the required information.